James Thomas (Partner, Thomas, McNerney & Partners and Director, Clarus Therapeutics, Inc.). Mr. Thomas is a co-founder of Thomas, McNerney & Partners and has been investing in health care companies since 1992. He previously headed Warburg Pincus LLC ("Warburg")’s medical technology private equity practice where he had responsibility for investments in biotechnology, pharmaceutical, medical device and diagnostic companies. During his 12-year tenure at Warburg, Mr. Thomas was directly involved in portfolio company investments totaling over $450 million. Historical investments include: American Medical Systems Holdings, Inc. (AMMD), The Medicines Company (MDCO), NeXagen, Inc. (NXGN/NXTR sold to GILD with spin-outs to EYET, Archemix and SomaLogic), OsteoBiologics, Inc. (sold to Smith & Nephew plc), Oxford GlycoSciences, plc (OGSI sold to CLL), Transkaryotic Therapies, Inc. (TKTX sold to SHPGY), Visible Genetics, Inc. (VGIN sold to BAY), Wright Medical Group, Inc. (WMGI) and Xomed Surgical Products, Inc. (XOMD sold to MDT). In addition to being a Director of Clarus, Mr. Thomas is currently a board member of Coley Pharmaceutical Group, Inc. (COLY), Galil Medical and Solstice Neurosciences, Inc. Prior to joining Warburg, Mr. Thomas was a Vice President at Goldman Sachs International in London, England. He graduated magna cum laude with a B.S. in Economics from the Wharton School at the University of Pennsylvania and received an M.Sc. in Economics from the London School of Economics.

Thomas, McNerney & Partners

<< Back